10 Key Strategies for First in Human Biopharma Trials in Bolivia

Introduction

In the competitive landscape of biopharmaceutical research, FIH trials in Bolivia offer both significant opportunities and formidable challenges. As the region emerges as a strategic hub for early-stage clinical studies, understanding the regulatory framework and operational nuances becomes crucial for success. Organizations must adopt strategic approaches to navigate these complexities and ensure timely market entry while maintaining compliance with local standards. This article outlines ten key strategies that can enhance the effectiveness of FIH trials in Bolivia, paving the way for transformative breakthroughs in healthcare.

Understand Regulatory Requirements for FIH Trials in Bolivia

Before embarking on first in human biopharma Bolivia studies, it is essential to understand AGEMED’s oversight framework for success. Key requirements include:

• Clinical Trial Application (CTA): A comprehensive CTA must be submitted, including the study protocol, informed consent forms, and qualifications of the investigators. Approval timelines show that the average approval time for clinical trials is between 60 to 90 days in first in human biopharma Bolivia, which is notably faster than many other regions, making it an attractive option for early-stage trials.
• Compliance Standards: Adherence to ICH-GCP guidelines is crucial to ensure that the data generated is acceptable to oversight bodies such as the FDA and EMA.
• Documentation: Thoroughly preparing all necessary documentation is crucial. It helps prevent delays in the approval process. This includes ensuring that all foreign certificates are legalized and translations are accurate.
• Engagement with Local Experts: Utilizing a Local Authorized Representative (LAR) or compliance consultant can significantly enhance the likelihood of a successful registration process, given their familiarity with local regulations and procedures.
• Buffer Time: Consider adding some buffer time to your market entry plan to handle any unexpected delays, as processing times can fluctuate based on AGEMED’s workload and backlog.

By mastering these compliance standards, companies can streamline their entry into the clinical research landscape of first in human biopharma Bolivia.

Choose the Right CRO for Your First-in-Human Trials

Navigating the complexities of first in human biopharma Bolivia studies requires careful selection of a Contract Research Organization (CRO). Here are key factors to consider:

• Experience with FIH Trials: Choose a CRO with a proven track record in managing FIH studies, especially within Bolivia’s regulatory landscape. This experience is vital for effectively navigating the challenges of early-phase studies.
• Local Knowledge: A CRO with deep local expertise can adeptly handle regulatory requirements set by authorities like INVIMA, ensuring quicker approvals and compliance with ICH-GCP standards.
• Patient Recruitment: To keep your clinical studies on track, effective patient recruitment is key. Ensure the CRO has established networks and strategies tailored to the Bolivian population, which can significantly boost recruitment success rates.
• Cost Efficiency: Evaluate the CRO’s pricing structure to ensure it aligns with your budget while maintaining high-quality services. A well-organized budget can prevent delays and unexpected expenses during the study.
• Regulatory Pathways: Understanding the submission pathways and compliance requirements specific to Bolivia will facilitate smoother interactions with regulatory bodies, ultimately speeding up the research process.

By making informed choices, healthcare startups can significantly enhance their chances of success in clinical research.

Prepare Comprehensive Preclinical Data for Approval

To secure approval for first in human biopharma Bolivia trials, startups must navigate a complex landscape of regulatory requirements and preclinical evidence. Preparing comprehensive preclinical evidence that demonstrates the safety and efficacy of your product is essential. Key components include:

• Toxicology Studies: Conduct thorough toxicology assessments to identify any potential adverse effects. These studies play a vital role in revealing how safe the drug really is and are typically required to be conducted in compliance with ICH-GCP guidelines.
• Pharmacokinetics and Pharmacodynamics: Provide detailed data on how the drug behaves in the body, including absorption, distribution, metabolism, and excretion, as well as its biological effects. This information is vital for understanding the drug’s therapeutic potential and safety.
• Risk Assessment: Include a comprehensive risk assessment that outlines potential risks associated with the drug and the strategies for mitigating these risks. This proactive approach is crucial for submission processes.
• Compliance with Guidelines: Ensure that all preclinical studies adhere to relevant standards, such as those established by the FDA and local authorities like INVIMA in Colombia, ANVISA in Brazil, and COFEPRIS in Mexico. Adhering to these guidelines is essential for the timely approval of studies related to first in human biopharma Bolivia.

Navigating the regulatory landscape can be a daunting task for startups, often leading to delays in their progress. However, in Latin America, the strategic advantages of conducting these studies include faster patient recruitment and reduced costs, enabling startups to navigate the ‘Valley of Death’ more effectively. By leveraging these advantages, startups can significantly reduce the time to market for their innovations.

Engage Local Stakeholders for Support and Guidance

Engaging local stakeholders is not just beneficial; it’s essential for the success of first in human biopharma Bolivia. Consider the following strategies:

• Identify Key Stakeholders: Collaborate with local healthcare providers, regulatory bodies such as INVIMA, and community leaders to gain insights and support. This collaboration is crucial for navigating the regulatory landscape and ensuring compliance with local requirements.
• Build Relationships: Establish strong connections with stakeholders to foster trust and facilitate smoother operational processes. Keeping the lines of communication open and providing regular updates can really boost stakeholder confidence and commitment.
• Community Engagement: Did you know that 57% of people cite a lack of trust as the main reason they don’t participate in clinical studies? That’s why community engagement is so vital to breaking down these barriers. Involving the community in the study process enhances participation rates and ensures ethical compliance.
• Leverage Local Expertise: Utilize local knowledge to navigate cultural nuances and improve patient recruitment strategies. Engaging with local healthcare professionals can provide insights into patient preferences and enhance recruitment efforts, leading to faster enrollment and more representative study populations.
• Monitor Engagement Metrics: Regularly assess stakeholder involvement and satisfaction through metrics such as participation rates and feedback scores. This ongoing evaluation helps refine engagement strategies and ensures alignment with project goals.

Ultimately, the success of clinical trials hinges on the strength of these local partnerships and the trust built within the community.

Ensure Ethical Compliance and Informed Consent

In first-in-human (FIH) studies, the stakes are high, making ethical compliance and a robust informed consent process non-negotiable. Key strategies include:

• Informed Consent Process: Develop clear and comprehensive informed consent forms that explicitly outline the trial’s purpose, potential risks, and benefits. How can transparency in participant rights build trust and ethical integrity in your studies? This clarity is crucial for participant understanding and engagement.
• Ethics Committee Approval: Obtain authorization from Bolivia’s National Health Authority (Ministerio de Salud) prior to commencing the study. Navigating the ethics committee approval process can introduce delays, impacting the overall timeline of the study. The typical duration for ethics committee approval in Bolivia is around 4 to 6 weeks, which is relatively quick compared to other areas, facilitating earlier initiation of studies and shortened time to market.
• Participant Rights: Ensure that participants are fully informed of their rights, including the right to withdraw from the study at any time without penalty. This transparency fosters trust and ethical integrity.
• Ongoing Monitoring: Establish ongoing oversight during the study to maintain ethical standards. This allows for prompt addressing of any emerging concerns. Regular assessments of participant comprehension and adherence to the informed consent process are essential, with an emphasis on incorporating participant feedback to improve the process.
• Cultural and Linguistic Considerations: Recognize the importance of cultural and linguistic factors when obtaining consent, ensuring that communication is effective and respectful of diverse populations.
• Updates for 2026: Stay informed about innovative strategies that enhance participant understanding and retention in the informed consent process, such as utilizing visual aids and interactive tools.

By prioritizing these elements, first in human biopharma Bolivia can navigate ethical complexities effectively, ensuring participant safety and regulatory compliance while leveraging the region’s advantages in speed and cost efficiency. Ultimately, prioritizing ethical standards not only safeguards participants but also paves the way for successful clinical advancements in the region.

Implement Effective Patient Recruitment Strategies

Recruiting patients for first in human biopharma Bolivia trials presents significant challenges that require strategic solutions. To enhance patient recruitment, consider the following strategies:

• Community Outreach and Local Partnerships: Engage local communities through informational sessions that highlight the trial’s benefits and address any concerns. Collaborate with local health organizations and advocacy groups to tap into established networks. This direct interaction fosters trust and enhances credibility, encouraging participation.
• Utilize Digital Platforms: Leverage social media and online platforms to disseminate information widely. With over 3.5 billion social media users globally, targeted digital campaigns can effectively reach individuals actively seeking treatment options.
• Tailored Messaging: Develop culturally sensitive messaging that resonates with the Bolivian population. Grasping local values and languages is essential for enhancing engagement and ensuring that the study’s purpose is clearly conveyed.
• Incentives for Participation: Offering rewards like monetary compensation or health benefits encourages individuals to participate in clinical studies. This strategy can really boost recruitment rates by making participation more attractive.
• Localized Lab Services: Collaborating with regional lab services can facilitate necessary in-person visits for decentralized studies, ensuring that patients can complete required tests conveniently, thus enhancing participation rates.
• Culturally Tailored Communication: Implementing communication strategies that align with the cultural context of the target population is essential. This promotes better comprehension and acceptance of clinical research, boosting participant enrollment.
• Follow-Up Services: Automated follow-up services, such as texts and emails, can gently remind potential participants to take action without being intrusive, helping maintain engagement and reducing drop-off rates.
• Screening for Multiple Trials: Utilizing online pre-screeners allows for efficient screening of patients for various trials simultaneously, simplifying the recruitment process and providing sponsors with valuable information.

Furthermore, it is crucial to take into account the compliance framework in Bolivia. Working with local authorities like INVIMA offers insights into compliance requirements and approval timelines, usually taking 4-8 weeks. By embracing these strategies, you can not only enhance recruitment but also ensure the success of your clinical trials in Bolivia.

Monitor Data Integrity and Compliance Throughout Trials

In the realm of first in human biopharma Bolivia studies, particularly in Latin America, the stakes are high when it comes to compliance and information integrity. Ensuring compliance and integrity of information is crucial, especially given the 4-8 week ethics approvals and cost efficiencies that can greatly enhance the clinical development process. Key practices include:

• Regular Audits: Conducting frequent audits of trial data is essential to promptly identify and rectify discrepancies, thereby enhancing data reliability and compliance with regulatory standards. What happens when compliance falters? Financial losses can be staggering, with direct costs nearing $525,000 and indirect costs soaring to about $1.3 million.
• Advanced Management Systems: Implementing sophisticated management systems allows for effective tracking and oversight of clinical information, ensuring adherence to protocols and compliance requirements such as ICH-GCP and FDA guidelines. Comprehensive staff training is crucial for maintaining compliance in first in human biopharma Bolivia, as it ensures that all personnel involved in information collection and management understand the protocols and ethical considerations involved in FIH trials.
• Real-Time Monitoring: With real-time monitoring systems, you can catch issues as they happen. This allows for quick corrective actions and helps maintain compliance with regulatory standards from authorities like INVIMA, ANVISA, and COFEPRIS.

Bauchner H pointed out that lapses in information integrity can lead to major revenue losses, highlighting just how crucial compliance really is. These practices not only protect data integrity but also leverage the strategic benefits of conducting studies in Latin America, where streamlined processes and cost efficiencies can significantly improve the clinical development process. Ultimately, the commitment to compliance not only safeguards data integrity but also positions organizations to capitalize on the unique advantages of the Latin American clinical landscape.

Adapt Trial Protocols to Local Conditions

In clinical research, honoring local traditions and practices is not just beneficial; it’s essential for participant engagement and study success. This method builds trust. It enhances recruitment and retention rates, leading to more successful study outcomes.

A thorough assessment of local healthcare infrastructure is essential. Protocols should be modified to align with the available resources and capabilities, ensuring that the study can be conducted effectively within the local context.

By understanding the specific characteristics of the patient population – like demographics and prevalent health conditions – we can customize protocols effectively. This guarantees that the study is pertinent and suitable for the participants involved.

How can collaboration with local oversight bodies like INVIMA in Colombia, ANVISA in Brazil, and COFEPRIS in Mexico enhance our studies? Ensuring that adaptations adhere to national regulations not only facilitates smoother execution of the studies but also enhances the likelihood of regulatory approval. In Latin America, the average timeline for ethics approval can range from 4 to 8 weeks, significantly faster than in many other regions. This velocity can be utilized to expedite the overall study timeline, enabling faster information generation and advancement to subsequent phases.

Furthermore, the cost-effectiveness of carrying out studies in this area is remarkable, with potential savings of $25K per patient due to pre-negotiated site agreements and 30% reduced overall study expenses. These savings can be reinvested into R&D or used to extend funding milestones, ultimately preserving equity and enhancing the potential for successful outcomes.

All protocols must adhere to ICH-GCP standards to ensure that the data generated is FDA and EMA ready. This adherence is vital for preserving the integrity of the study and ensuring that results are accepted by oversight bodies in the future. Without these adaptations, studies risk losing participant trust and ultimately jeopardizing their success.

Leverage Technology for Streamlined Trial Processes

In the rapidly evolving landscape of clinical research, integrating technology into first in human biopharma Bolivia trials is not just beneficial; it’s essential for success. Especially in Latin America, where leveraging these advantages can significantly accelerate trial timelines. Key technologies to consider include:

• Electronic Data Capture (EDC): EDC systems are crucial for enhancing data accuracy and minimizing errors linked to manual entry. They facilitate real-time information gathering, ensuring compliance with standards like ICH-GCP and FDA requirements. Implementing EDC has been proven to speed up study timelines and lead to substantial cost savings throughout a study’s lifecycle. In Latin America, EDC systems align with regulatory frameworks established by authorities such as INVIMA in Colombia, ANVISA in Brazil, and COFEPRIS in Mexico, expediting the approval process and improving market access strategies.
• Remote Monitoring Tools: Utilizing remote monitoring tools fosters continuous patient engagement and real-time data collection, which is vital for maintaining participant retention. With these tools, patients can easily report outcomes using devices they already know, making their experience smoother and boosting their participation in the study. Statistics show that remote monitoring can enhance retention rates by up to 30%, making it an essential element of first in human biopharma Bolivia studies, especially in the fast-paced regulatory landscape of Latin America.

Leveraging Artificial Intelligence (AI) can enhance patient recruitment and analysis, improving both accuracy and speed. AI technologies can analyze large datasets to identify patterns and predict outcomes, which is especially advantageous in the context of FIH studies where timely data is critical. The integration of AI can reduce recruitment timelines by 25%, allowing for quicker patient enrollment, thus capitalizing on the region’s strategic advantages.

• Telemedicine Solutions: Implementing telemedicine for follow-ups and consultations alleviates the strain on participants, facilitating their engagement throughout the study. This method not only improves retention rates but also aligns with the increasing trend of decentralized studies, which have gained momentum since the COVID-19 pandemic. Research indicates that telemedicine can boost patient satisfaction by 40%, further enhancing participant retention in the context of first in human biopharma Bolivia studies.

Applying these technologies strategically in Latin America accelerates the clinical research process and takes advantage of the region’s regulatory benefits. This enables quicker patient recruitment and more effective market access.

Utilize bioaccess for Tailored Support in FIH Trials

Conducting first in human biopharma Bolivia trials offers unique opportunities and challenges for startups in the MedTech sector. Partnering with bioaccess offers several advantages for conducting these trials:

• Specialized Expertise: As the world’s first CRO dedicated exclusively to FIH trials, bioaccess provides tailored support that aligns with the unique needs of startups in the MedTech, Biopharma, and Radiopharmaceutical sectors.
• Accelerated Timelines: With an average ethics approval duration of just 4-6 weeks, bioaccess significantly reduces the time to begin studies compared to traditional CROs, which often take 6-12 months. This quick turnaround helps startups keep their development on track.
• Cost Efficiency: bioaccess’s innovative approach can reduce study costs by up to 30%, translating to savings of approximately $25,000 per patient. This financial viability is crucial for startups with limited budgets.
• Comprehensive Services: bioaccess oversees the entire clinical study process, from regulatory submissions to patient recruitment, ensuring a streamlined approach that enhances efficiency and accelerates progress toward clinical milestones. This comprehensive service model allows clients to navigate the complexities of local regulations, such as those set by INVIMA, while ensuring compliance with ICH-GCP standards.
• Faster Patient Recruitment: Leveraging extensive local networks, bioaccess achieves patient enrollment rates that are 50% faster than conventional CROs, addressing one of the most significant challenges in clinical trials-prolonged recruitment periods that can drain resources and delay critical timelines.

By choosing bioaccess, startups can avoid these pitfalls and accelerate their path to market, ensuring timely market entry and successful outcomes.

Conclusion

Navigating the complex regulatory landscape of first-in-human biopharma trials in Bolivia can be daunting, yet it offers significant opportunities for MedTech and biopharma startups. Understanding and adhering to regulatory requirements is crucial. Engaging local stakeholders and implementing effective patient recruitment strategies can significantly streamline trial processes and enhance chances of success. The strategic advantages of conducting these trials in Latin America, including faster approval timelines and cost efficiencies, further reinforce the potential for rapid market entry and innovative advancements.

Key strategies discussed include:

1. Selecting the right Contract Research Organization (CRO) with local expertise
2. Preparing comprehensive preclinical data for regulatory approval
3. Ensuring ethical compliance throughout the study

These elements are vital for meeting regulatory standards and building trust with the local community, which is crucial for participant recruitment and retention.

By leveraging technology, startups can transform these challenges into opportunities for growth. Tailored support services from specialized CROs like bioaccess enhance efficiency and effectiveness in trial execution. By prioritizing compliance and ethical standards, startups not only protect participants but also position themselves at the forefront of healthcare innovation.

Frequently Asked Questions

What are the key regulatory requirements for conducting first-in-human (FIH) trials in Bolivia?

Key regulatory requirements include submitting a comprehensive Clinical Trial Application (CTA), adhering to ICH-GCP compliance standards, preparing thorough documentation, engaging with local experts, and allowing for buffer time in the market entry plan.

How long does it typically take to get approval for clinical trials in Bolivia?

The average approval time for clinical trials in Bolivia is between 60 to 90 days, which is notably faster than many other regions.

Why is compliance with ICH-GCP guidelines important for FIH trials?

Compliance with ICH-GCP guidelines is crucial to ensure that the data generated is acceptable to oversight bodies such as the FDA and EMA.

What documentation is necessary for the Clinical Trial Application (CTA)?

The CTA must include the study protocol, informed consent forms, and qualifications of the investigators, along with any necessary foreign certificates that need to be legalized and accurately translated.

How can local expertise enhance the registration process for clinical trials in Bolivia?

Utilizing a Local Authorized Representative (LAR) or compliance consultant can significantly enhance the likelihood of a successful registration process due to their familiarity with local regulations and procedures.

What factors should be considered when choosing a Contract Research Organization (CRO) for FIH trials?

Important factors include the CRO’s experience with FIH trials, local knowledge of regulatory requirements, patient recruitment strategies, cost efficiency, and understanding of regulatory pathways specific to Bolivia.

What role does patient recruitment play in the success of clinical studies?

Effective patient recruitment is key to keeping clinical studies on track, and a CRO with established networks and tailored strategies for the Bolivian population can significantly boost recruitment success rates.

What are the essential components of preclinical data needed for approval?

Essential components include toxicology studies, pharmacokinetics and pharmacodynamics data, a comprehensive risk assessment, and compliance with relevant guidelines set by authorities like the FDA and INVIMA.

How can startups navigate the regulatory landscape for FIH trials in Bolivia?

Startups can navigate the regulatory landscape by preparing comprehensive preclinical evidence, adhering to local and international guidelines, and leveraging the strategic advantages of faster patient recruitment and reduced costs in Latin America.

What advantages does conducting FIH trials in Latin America offer?

Conducting FIH trials in Latin America offers strategic advantages such as faster patient recruitment, reduced costs, and more efficient regulatory pathways, which can significantly shorten the time to market for innovations.

List of Sources

1. Understand Regulatory Requirements for FIH Trials in Bolivia
   • omcmedical.com (https://omcmedical.com/blog/bolivia-medical-device-registration-process-timelines)
   • ftp.bills.com.au (https://ftp.bills.com.au/lunar-tips/bolivias-drug-regulatory-authority-a-comprehensive-overview-1767648693)
   • clinicaltrialsarena.com (https://clinicaltrialsarena.com/news/can-regulatory-reform-unearth-latams-untapped-potential-for-drug-development)
   • bioaccessla.com (https://bioaccessla.com/blog/designing-clinical-trials-for-medical-devices-in-bolivia-key-steps)
2. Choose the Right CRO for Your First-in-Human Trials
   • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC12474682)
   • bioaccessla.com (https://bioaccessla.com/blog/how-to-choose-a-cro-for-first-in-human-trials-in-bolivia)
   • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
   • First-in-Human Clinical Trial CRO — U.S. & Latin America | bioaccess® (https://bioaccessla.com/first-in-human-cro)
   • novotech-cro.com (https://novotech-cro.com/blog/choosing-right-cro-your-clinical-trial)
3. Prepare Comprehensive Preclinical Data for Approval
   • appliedclinicaltrialsonline.com (https://appliedclinicaltrialsonline.com/view/fda-actions-reshaping-drug-development-2026)
   • stocktitan.net (https://stocktitan.net/news/CURX/curanex-achieves-key-preclinical-milestone-with-favorable-toxicology-mnontwb31lb1.html)
   • biopharmaservices.com (https://biopharmaservices.com/blog/phase-1-which-requirements-must-be-met-to-conduct-first-in-human-clinical-trials)
   • tfscro.com (https://tfscro.com/resources/bridging-the-gap-how-strategic-resourcing-accelerates-biotechs-path-from-preclinical-to-fih)
   • content.noblelifesci.com (https://content.noblelifesci.com/blog/preclinical-toxicology-considerations-for-successful-ind-application)
4. Engage Local Stakeholders for Support and Guidance
   • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC11795857)
   • petauri.com (https://petauri.com/insights/identifying-the-stakeholders-vital-to-clinical-trial-success)
   • nclusiv.co.uk (https://nclusiv.co.uk/edi-consulting/f/patient-engagement-quotes-for-every-purpose-audience)
   • Stakeholder Engagement Effectiveness Statistics (https://zoetalentsolutions.com/stakeholder-engagement-effectiveness)
5. Ensure Ethical Compliance and Informed Consent
   • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC4943379)
   • azquotes.com (https://azquotes.com/quotes/topics/clinical-trials.html)
   • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10760836)
6. Implement Effective Patient Recruitment Strategies
   • worldbank.org (https://worldbank.org/en/news/press-release/2026/02/05/world-bank-group-approves-us-200-million-to-protect-vulnerable-bolivians-and-strengthen-social-protection)
   • antidote.me (https://antidote.me/blog/10-clinical-trial-recruitment-strategies-that-work)
   • finance.yahoo.com (https://finance.yahoo.com/news/women-clinical-trials-5-quotes-161500798.html)
   • bioaccessla.com (https://bioaccessla.com/blog/9-patient-recruitment-strategies-for-bolivian-trials)
7. Monitor Data Integrity and Compliance Throughout Trials
   • veedalifesciences.com (https://veedalifesciences.com/data-integrity-in-clinical-research)
   • gmppros.com (https://gmppros.com/pharma-compliance)
   • Quotes Related to Data and Data Governance (https://blog.idatainc.com/quotes-related-to-data-and-data-governance)
   • pipeline.zoominfo.com (https://pipeline.zoominfo.com/operations/19-inspirational-quotes-about-data)
8. Adapt Trial Protocols to Local Conditions
   • unfpa.org (https://unfpa.org/resources/quotes-culture-and-culturally-sensitive-approaches)
   • signanthealth.com (https://signanthealth.com/resources/blog/cultural-competence-and-cultural-humility-in-clinical-trials-1)
   • clinicalleader.com (https://clinicalleader.com/doc/cultural-competence-and-cultural-humility-in-clinical-trials-0001)
9. Leverage Technology for Streamlined Trial Processes
   • clinicalink.com (https://clinicalink.com/from-data-to-insight-leveraging-technology-for-clinical-trial-success)
   • viedoc.com (https://viedoc.com/blog/key-benefits-electronic-data-capture-clinical-trials)
   • credevo.com (https://credevo.com/articles/2024/05/05/electronic-data-capture-in-clinical-trials-impact-advantages)
   • bioaccessla.com (https://bioaccessla.com/blog/how-to-leverage-technology-for-trial-design-a-step-by-step-guide)
10. Utilize bioaccess for Tailored Support in FIH Trials

• 7 Reasons Bioaccess Is The Best Cro For Radiopharmaceutical Phase I Studies | bioaccess® (https://bioaccessla.com/blog/7-reasons-bioaccess-is-the-best-cro-for-radiopharmaceutical-phase-i-studies)
• globaltrialaccelerators.com (https://globaltrialaccelerators.com/robert-packard-medical-device-academy)
• bioaccessla.com (https://bioaccessla.com/blog/master-first-in-human-clinical-trials-in-latin-america-a-complete-guide)
• bioaccessla.com (https://bioaccessla.com/blog/understanding-bioaccess-clinical-trials-a-new-era-for-startups)